RxDoctor Payments DataLook up a doctor →

Ashkan Abbey, MD

Ophthalmology · Dallas, TXNPI 1548402886

Payments from drug & device makers

$5,717,136in general payments, 2019–2025

Across 1,162 payments — averaging $4920.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$2.6M
  • AbbVie$1M
  • Eyepoint US, Inc.$554K
  • Apellis Pharmaceuticals, Inc.$387K
  • Regeneron$193K
  • Sanofi US Services Inc.$183K
  • plus $827K from 36 others
$92,726in research payments, 2019–2025

Across 19 payments — averaging $4880.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alimera Sciences, Inc.$78K
  • Ocular Therapeutix, Inc.$11K
  • Regeneron$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.156$2,569,370
AbbVie(2 entities)113$1,003,472
Eyepoint US, Inc.37$553,888
Apellis Pharmaceuticals, Inc.165$387,346
Regeneron77$193,324
Sanofi US Services Inc.10$182,739
Regeneron Healthcare Solutions, Inc.154$122,051
Amgen(2 entities)12$107,079
Janssen Research & Development, LLC20$99,709
Ocular Therapeutix, Inc.9$83,089
Novartis54$82,446
Hoffmann-la Roche Limited5$60,827
Genentech USA, Inc.68$57,013
Astellas Pharma US Inc42$47,052
Alimera Sciences, Inc.64$40,825
ANI Pharmaceuticals, Inc.8$32,347
F. Hoffmann-la Roche AG4$22,422
Biogen15$17,915
Bausch & Lomb Americas Inc.29$9,395
Novartis Pharma AG3$9,225
Alcon Research LLC10$7,946
Alcon21$7,394
Coherus Oncology, Inc.20$6,935
Neurotech Pharmaceuticals, Inc.8$4,131
Harrow Eye, LLC12$3,285
Thrombogenics, Inc.3$2,057
Beaver-visitec International, Inc.2$1,550
Boehringer Ingelheim International GmbH12$962
Samsara Vision1$489
Sandoz10$275
Carl Zeiss Meditec USA, Inc.1$109
Carl Zeiss Meditec, Inc.1$70
Kala Pharmaceuticals, Inc.3$64
Bausch & Lomb, A Division Of Bausch Health US, LLC3$60
Astellas Pharma Global Development2$59
Iridex Corporation1$58
Topcon Healthcare, Inc.1$40
Halozyme Inc2$33
Takeda Pharmaceuticals U.S.A., Inc.1$27
Biotissue Holdings Inc.1$24
Vyera Pharmaceuticals, LLC1$23
Notal Vision, Inc.1$14

How this compares

$5,717,136 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas →

Medicare billing

Part B allowed, 2024
$9,076,905
Medicare patients
1,633
Services billed
127,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →